

Consistent Outcomes Across EBV RCTs in Patients without Collateral Ventilation



RCT	Design	Sample size & Follow-up period	Difference EBV vs Control Groups		
			Lung Function (FEV ₁ %) MCID = 10%-15%	Exercise Capacity (6MWD) MCID = 26 m	Quality of Life (SGRQ) MCID = - 4 pts
LIBERATE ¹	2:1 Randomization Heterogeneous only Multi-Center	n=190 12 months	18.0 %*	39.3 m*	-7.1 pts*
TRANSFORM ²	2:1 Randomization Heterogeneous only Multi-Center	n=97 6 months	29.3 %*	79 m*	-6.5 pts*
IMPACT ³	1:1 Randomization Homogeneous only Multi-Center	n=93 6 months	16.3 %*	28 m*	-7.5 pts*
STELVIO ⁴	1:1 Randomization Heterogeneous & Homogeneous Single Center	n=68 6 months	17.8 %*	74 m*	-14.7 pts


Complications of endobronchial valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, pneumonia, dyspnea and, in rare cases, death.

* Intent-to-Treat population

¹ Criner et al. Am J Resp Crit Care Med.2018, in press | ² Kemp S et al. Am J Resp Crit Care Med 2017; (196)12: 1535-1543 | ³ Valipour et al. Am J Respir Crit Care Med. 2016; Vol 194, Iss 9, pp 1073-1082 and Data on file at Pulmonx | ⁴ Klooster K. et al. N Engl J Med. 2015; 373: 2325-2336 + Supplementary Appendix

Proven Tools for Patient Selection and Personalized Treatment

90% Combined Accuracy of StratX® Lung Analysis and Selective Use of Chartis



StratX Lung Analysis Platform* Chartis Pulmonary Assessment System*

Source: Koster TD, et al. Predicting Lung Volume Reduction after Endobronchial Valve Therapy Is Maximized Using A Combination of Diagnostic Tools. Respiration. 2016 (in press).

Zephyr® valve treatment of severe emphysema is included in global and national guidance documents, such as those sponsored by:

- Global Initiative for Chronic Obstructive Lung Disease (GOLD)
- Australian Lung Foundation (COPD-X)
- German Respiratory Society (DGP)
- The UK's National Institute for Care and Excellence (NICE)
- National Health Care Institute of the Netherlands (Zorginstituut Nederland)



12,000+ Patients Treated
with Zephyr® Endobronchial Valves

Source: Supplementary appendix STELVIO Trial 'Endobronchial valves for emphysema without interlobar collateral ventilation' Klooster et al. Nov 18, 2015, p 30.

Contact us for more information: info@pulmonx.com

Pulmonx International Sàrl

Rue de la Treille 4, 2000 Neuchâtel, Switzerland
Tel.: +41 32 475 20 70, Fax: +41 32 475 20 71

Pulmonx Corporation

700 Chesapeake Drive, Redwood City CA USA 94063
Tel.: +1 650 364 0400, Fax: +1 650 364 0403

*Availability of Chartis console models may vary by country. StratX is currently not available in the United States. The Zephyr® Endobronchial Valve is an investigational device in the United States. Limited by US law to investigational use only.



Visit our website: www.pulmonx.com